



**COMMONWEALTH OF KENTUCKY
CABINET FOR HEALTH AND FAMILY SERVICES
DEPARTMENT FOR MEDICAID SERVICES
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING**
NOTE: This special-called meeting will be held virtually via Microsoft Teams webinar.
Tuesday, April 21, 2026
1:00 P.M. to 4:00 P.M. (Eastern)

Smartphone/Web	Dial-In by Phone
<p>Microsoft Teams</p> <p>Join the meeting now</p> <p>Meeting ID: 225 956 973 145 06</p> <p>Passcode: hg9By9ZV</p> <p>Download Teams Join on the web</p>	<p>+1 858-252-2734 (United States)</p> <p>Phone conference ID: 718 536 178#</p>

AGENDA

- I. Call to Order and Welcome**
- II. Executive Session (Upon Request)**
- III. Old Business**
 - a. Approval of July 2025 Meeting Minutes
 - b. Approval of October 2025 Meeting Minutes
 - c. Approval of January 2026 Meeting Minutes
 - d. Presentation of Itvisma® (onasemnogene abeparovvec-brve) Clinical Criteria
- IV. New Business**
 - a. New Products to Market to be Reviewed as Single Products
 - i. Palsonify™ (paltusotine) – Non-PDL
 - ii. Voyxact® (sibeprenlimab-szsi) – Non-PDL
 - iii. Attruby™ (acoramidis) – Non-PDL
 - iv. Redemplo® (plozasiran) – Non-PDL
 - v. Exdensur (depemokimab-ulaa) – Non-PDL
 - vi. Forzinity™ (elamipretide) – Non-PDL
 - vii. Aqvesme™ (mitapivat) – Non-PDL
 - viii. Pivya (pivmecillinam) – Non-PDL
 - ix. Zycubo® (copper histidinate) – Non-PDL
 - x. Cardamyst™ (etripamil) – Non-PDL
 - xi. Myqorzo™ (aficamten) – Non-PDL
- V. Therapeutic Classes with Recommended PDL Status Changes**
 - a. Bone Resorption Suppression and Related Agents
 - b. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors





- c. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

VI. Therapeutic Classes with Recommended Structure Changes (No PDL Status Changes)

- a. Colony Stimulating Factors
- b. Steroids, Topical

VII. Consent Agenda

- a. The following therapeutic classes have no recommended changes and may be voted on as a group under a consent agenda

<ul style="list-style-type: none"> • Narcotic Agonist/Antagonists • Narcotics, Fentanyl Buccal Products • Narcotics, Long-Acting • Narcotics, Short-Acting • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) • Opiate Dependence Treatments • Antihyperuricemics • Erythropoiesis Stimulating Proteins • Phosphate Binders • Sickle Cell Anemia Treatments • Thrombopoiesis Stimulating Proteins • Alpha-Glucosidase Inhibitors • Insulins and Related Agents 	<ul style="list-style-type: none"> • Meglitinides • Metformins • Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors • Sulfonylureas • Thiazolidinediones (TZDs) • Androgenic Agents • Glucagon Agents • Growth Hormone • Pancreatic Enzymes • Progestins for Cachexia • Steroids, Oral • Uterine Disorder Treatments
---	--

VIII. Adjournment

- a. Schedule of Upcoming Meetings
 - i. July 21, 2026
 - ii. October 13, 2026

To view the most current Preferred Drug List (PDL) and Prior Authorization (PA) criteria, please go to <https://kyportal.medimpact.com/provider-documents/drug-information>.

PUBLIC SPEAKERS: If you would like to speak during the public session, please complete the Speaker Request form located on the Committee Information tab under the Forms section at <https://kyportal.medimpact.com/provider-documents/pt-committee>.

